Phase 3 clinical trials of the Novavax Covid 19 vaccine are set to start in the United States and Mexico , the company announced on Monday . 
The trial for the vaccine candidate , known as NVX Co V2373 , will evaluate safety , efficacy and immune response in up to 30,000 people age 18 and older . 
It builds on Phase 1 and 2 studies that demonstrated the vaccine provoked an immune response and appeared to be safe . 
The trial is examining whether the vaccine prevents moderate Covid 19 symptoms , as well as severe Covid 19 symptoms . 
Two thirds of participants will be assigned to randomly receive two injections of vaccine administered 21 days apart , the remaining one third will receive a placebo . 
The trials sites are in locations that currently have high transmission rates " to accelerate the accumulation of positive cases that could show efficacy , " a statement said . 
Novavax says it aims for at least 25 % of the study population to be age 65 or older , at least 15 % to be Black , at least 10 to 20 % Latinx and 1-2 % American Indian . 
The trial is being funded with up to $ 1.6 billion from Operation Warp Speed . 
Some background : Novavax is also currently conducting a Phase 3 clinical study in the United Kingdom , a Phase 2b trial in South Africa and a Phase 1/2 continuation in the US and Australia , data from which are expected as soon as early first quarter 2021 . 
Two coronavirus vaccines , those made by Pfizer/Bio NTech and Moderna , have received emergency use authorization from the US Food and Drug Administration . 
Two more vaccines , those from Johnson & Johnson and Astra Zeneca , are in Phase 3 trials in the United States . 
Watch Dr . Carlos Del Rio : 
